Nemolizumab (Nemluvio)

Canada’s Drug Agency (CDA-AMC) recommends that Nemluvio be reimbursed by public drug plans for the treatment of adult patients with moderate to severe prurigo nodularis (PN) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable if certain conditions are met. Nemluvio should only be covered to treat adult patients with moderate to severe PN, which was diagnosed by a dermatologist, who have had an inappropriate response to an appropriate course of topical prescription therapy, and in alignment with criteria used in the jurisdictions for the initiating, renewing, and prescribing of other advanced systemic treatments for PN. Nemluvio should only be reimbursed if the patient is under the care of a dermatologist with expertise in the management of PN and if the cost of Nemluvio is reduced. Nemluvio should be reimbursed for an initial 6-month period and continued thereafter only if there is documented evidence of a clinically meaningful reduction in itch and lesion count. Nemluvio should not be used in combination with other systemic therapies for PN.